Supplement Claims Substantiation: FTC, EFSA, ASA and the Global Evidence Dossier

FTC enforces against deceptive advertising under section 5 of the FTC Act. The applicable substantiation standard is 'competent and reliable scientific evidence' — defined by FTC and reinforced by consent orders and the 2022 Health Products Compliance Guidance as tests, analyses, research, studies or other evidence based on the expertise of professionals in the relevant area, conducted and evaluated in an objective manner by persons qualified to do so, using procedures generally accepted in the profession to yield accurate and reliable results. For supplement claims, FTC has consistently signalled an expectation of human clinical evidence — randomised, controlled, peer-reviewed trials — for the specific finished product or for the active at the dose, form and population represented in the claim. The standard is highest for disease claims (which trigger drug regulation) and remains substantial for structure/function and weight-loss claims. FTC enforcement actions against supplement brands routinely cite the absence of clinical evidence on the as-marketed product, over-extrapolation from in vitro or animal data, and reliance on ingredient evidence that does not translate to the formulation as sold. The 2022 guidance increased FTC's emphasis on requiring two adequate and well-controlled clinical trials for substantial health claims, particularly in weight loss, immune support and serious-condition adjacent categories.

DSHEA section 403(r)(6) authorises structure/function claims — statements that describe the role of a nutrient or dietary ingredient intended to affect the structure or function of the body, the mechanism of action by which it acts, or general well-being from consumption — provided the claim is truthful and not misleading, the manufacturer has substantiation, the FDA-mandatory disclaimer accompanies the claim, and the manufacturer notifies FDA within 30 days of first marketing using Form 3952. Disease claims — statements that the product diagnoses, treats, cures, prevents or mitigates a disease — are not permitted for dietary supplements and convert the product to a drug requiring FDA approval. The boundary is more porous than label-writers expect: FDA Warning Letters routinely cite claims like 'supports cardiovascular health in people with hypertension' as crossing into disease (the qualifier specifying a disease state), 'helps maintain blood sugar already in the normal range' as borderline (saved by the qualifier), 'boosts immune system to fight viruses' as crossing into disease (the implied disease target). The boundary applies to all marketing channels — label, website, social media, influencer content, podcast sponsorships, retailer-page bullet points and customer-service responses — and FDA increasingly cites digital and influencer content in Warning Letters.

EU Regulation (EC) 1924/2006 on Nutrition and Health Claims governs health claims on food and food supplements in the European market. Health claims are divided into Article 13 (general function claims — historical or established function claims on a positive list maintained by EFSA in the EU Register of nutrition and health claims, with authorised wording and conditions of use), Article 13.5 (newly developed scientific evidence claims), and Article 14 (reduction of disease risk claims and claims referring to children's development and health, requiring individual EFSA scientific assessment and Commission authorisation). The list of authorised claims is closed — a claim not on the EU Register is not permitted in EU food supplement marketing, regardless of underlying evidence. Authorised claims must be used with the authorised wording (or wording with the same meaning), the prescribed conditions of use (typically a minimum dose for the bioactive to qualify), and may not be misleading or imply broader effect. Botanical claims remain in regulatory limbo — most are 'on hold' pending review and may continue to be used under specific conditions but face increasing member state enforcement. EFSA's evidentiary bar for new Article 13.5 and 14 claims is high: well-conducted human intervention studies in the target population, biological plausibility, totality-of-evidence assessment — most submissions are not authorised.

UK ASA and CAP Code: the UK Advertising Standards Authority enforces the CAP (Committee of Advertising Practice) Code for non-broadcast advertising including websites and social media, with food supplement-specific provisions (Section 15 of the CAP Code) requiring substantiation of health claims, restriction to EU Register-authorised claims (retained UK law post-Brexit, with the UK Nutrition and Health Claims Committee taking over EFSA's role for new claims), and prohibition of medicinal claims that would require MHRA marketing authorisation. ASA rulings are publicly published and influence search engine and retailer policies — repeated adverse rulings can lead to referral to trading standards or MHRA. Health Canada NHP: claims must be authorised on the Product Licence (NPN) — health claims are reviewed pre-market with evidence ranging from traditional use (for traditional botanicals and homeopathic monographs) to modern clinical evidence (for non-traditional claims), and unauthorised claims trigger product licence suspension. Australia TGA (listed medicines): permitted indications drawn from a published list with associated evidence requirements; claims outside the permitted list require sponsor evidence and may not be made on listed medicines. The international pattern: pre-market authorisation of health claims is becoming the norm in major markets; the US FTC post-market substantiation model is increasingly the outlier.

A defensible global claims programme builds the evidence dossier once and licenses claim use per jurisdiction. Components: (1) the primary substantiation file — clinical study reports, peer-reviewed publications, meta-analyses and systematic reviews on the specific ingredient at the dose, form and population; (2) the dose-form-population matching analysis demonstrating that the as-marketed product corresponds to the evidence (the most common gap source); (3) the EU Register or per-market authorisation status with authorised wording, conditions of use and any restrictions; (4) the FTC-style competent and reliable scientific evidence assessment for jurisdictions on the post-market substantiation model; (5) the structure/function vs disease classification with the FDA Form 3952 notification where applicable; (6) the country-of-marketing routing decisions linking each claim wording to the destinations where it is authorised. The claims approval workflow gates every piece of marketing content (label, website, social, influencer, retailer page, sales deck, customer-service response) against the per-market claim register. Failure patterns: a sales deck citing an unsubstantiated claim, an influencer post making a disease claim, a multi-market e-commerce listing using US claims on the EU domain, a retailer page bullet point added by the retailer without claim review.